Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Kun-Liang Guan
University of California, San Diego, Department: Ophthalmology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Vivace Therapeutics, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Guan is a co-founder of Vivace Therapeutics, Inc. (Vivace) and holds (b)(4) equity interest in the company. The company focus is to develop inhibitors of YAP and TAZ to target cancer. The goals of this project are to determine the contributions of the genes commonly mutated in uveal melanoma and their functional interaction in promoting tumorigenesis of uveal melanoma.
Molecular Mechanism and Therapy for Ocular Melanoma
Narrative Cancer genetic analyses have revealed the major genes, including GNAQ, GNA11, BAP1, EIF1AX, and SF3B1, associated with ocular melanoma. We have observed that dysregulation of the Hippo tumor suppressor pathway by constitutively active mutations in GNAQ/11 plays a critical role in ocular melanoma tumorigenesis. The major goals of this proposal are to understand the functional interaction of genes mutated in ocular melanoma and identify therapeutic avenues for this deadly ocular cancer.
Filed on April 19, 2017.
Tell us what you know about Kun-Liang Guan's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Kun-Liang Guan filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Kun-Liang Guan | University of California, San Diego | Conflict of Interest | Vivace Pharmaceuticals | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.